Correlation between PSA kinetics and PSMA-PET in prostate cancer restaging: A meta-analysis.

Détails

ID Serval
serval:BIB_19E0E244B875
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Correlation between PSA kinetics and PSMA-PET in prostate cancer restaging: A meta-analysis.
Périodique
European journal of clinical investigation
Auteur(s)
Pereira Mestre R., Treglia G., Ferrari M., Pascale M., Mazzara C., Azinwi N.C., Llado' A., Stathis A., Giovanella L., Roggero E.
ISSN
1365-2362 (Electronic)
ISSN-L
0014-2972
Statut éditorial
Publié
Date de publication
03/2019
Peer-reviewed
Oui
Volume
49
Numéro
3
Pages
e13063
Langue
anglais
Notes
Publication types: Journal Article ; Meta-Analysis ; Systematic Review
Publication Status: ppublish
Résumé
Serum prostate-specific antigen (PSA) may predict the risk of positive positron emission tomography/computed tomography with radiolabelled prostate-specific membrane antigen (PSMA-PET/CT) in patients with biochemical recurrent prostate cancer (BRPCa). However, to date, there are no clear data regarding the correlation between PSA kinetics and PSMA-PET findings. We performed a systematic review and meta-analysis to provide evidence-based data in this setting.
A comprehensive literature search of studies published through October 2018 in PubMed/MEDLINE, EMBASE and Cochrane library databases was performed. A meta-analysis to establish the detection rate (DR) of PSMA-PET using different cut-off values of PSA doubling time (PSAdt) and a pooled analysis to establish whether shorter PSAdt may predict positive PSMA-PET results was performed in patients with BRPCa.
Twelve articles were included in the systematic review, and eight articles (including about 1400 patients) were selected for the meta-analysis. The pooled DR including 95% confidence intervals (95%CI) of PSMA-PET in restaging prostate cancer (PCa) patients was 72% (95%CI:60%-82%), increasing to 83% (95%CI:75%-90%) when PSAdt was ≤6 months and decreasing to 60% (95%CI:37%-80%) when PSAdt was >6 months, without a statistical significant difference. PSAdt ≤6 months may predict the positive result of PSMA-PET (pooled odds ratio: 3.22; 95%CI:1.17-8.88). Statistical heterogeneity among the included studies was found.
PSA kinetics, and in particular shorter PSAdt, may be predictor of PSMA-PET positivity in patients with BRPCa. Further larger studies in this setting are warranted.
Mots-clé
Adult, Aged, Aged, 80 and over, Antigens, Surface/metabolism, Biomarkers, Tumor/metabolism, Glutamate Carboxypeptidase II/metabolism, Humans, Male, Middle Aged, Neoplasm Staging, Positron Emission Tomography Computed Tomography, Prostate-Specific Antigen/metabolism, Prostatic Neoplasms/diagnosis, PSA doubling time, PSA kinetics, positron emission tomography, prostate cancer, prostate-specific antigen, prostate-specific membrane antigen
Pubmed
Web of science
Création de la notice
20/01/2019 17:07
Dernière modification de la notice
20/08/2019 13:51
Données d'usage